SPA
AUPH icon

Sherbrooke Park Advisers’s Aurinia Pharmaceuticals AUPH Stock Holding History

Sherbrooke Park Advisers’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-36,471
Closed -$309K – 522
2025
Q2 		$309K Buy
36,471
+5,450
+18% +$43.7K 0.13% 300
2025
Q1 		$249K Buy
+31,021
New +$251K 0.12% 357
2024
Q4 		– Sell
-25,392
Closed -$186K – 772
2024
Q3 		$186K Buy
+25,392
New +$157K 0.04% 769
2024
Q2 		– Sell
-23,017
Closed -$115K – 903
2024
Q1 		$115K Buy
+23,017
New +$156K 0.02% 785

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Sherbrooke Park Advisers's AUPH Position: Q3 2025 in Review

Sherbrooke Park Advisers sold out of Aurinia Pharmaceuticals (AUPH) in Q3 2025, closing a stake of 36,471 shares — an estimated $309K sold.

Sherbrooke Park Advisers first reported a position in AUPH in Q1 2024 and held it in 4 quarters. The position peaked at $309K in Q2 2025. 242 funds tracked by Wall St. Rank hold AUPH as of Q3 2025.

  • Sherbrooke Park Advisers reported no remaining Aurinia Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 36,471 Aurinia Pharmaceuticals shares in Q3 2025, an estimated $309K.
  • Sherbrooke Park Advisers first reported a position in Aurinia Pharmaceuticals in Q1 2024 and held it in 4 quarters.
  • Sherbrooke Park Advisers's Aurinia Pharmaceuticals position peaked at $309K in Q2 2025.
  • 242 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q3 2025, filed 14 Nov 2025.